Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.40 |
| ▸ | TOP1 | P11387 | 2/20 | 0.39 |
| ▸ | HRAS | P01112 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125589 | 1.00 | HDAC1 (0.53) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL30125591 | 0.97 | HDAC1 (0.57) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL23745119 | 0.97 | HDAC1 (0.53) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL28984141 | 0.95 | HDAC1 (0.48) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL30125597 | 0.94 | HDAC1 (0.49) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL4100605 | 0.93 | HDAC1 (0.46) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL25705072 | 0.92 | HDAC1 (0.46) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL25207599 | 0.91 | HDAC1 (0.48) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL25207597 | 0.91 | HDAC1 (0.55) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL23728729 | 0.91 | HDAC1 (0.55) | HDAC1HDAC2HDAC8ERBB2TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. | 2024-10-31 | — | — | US | disclosed |
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-115768765-A | Methods and compounds for treating genetic diseases | 设计治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | HDAC1 551/4885HDAC2 1636/4885HDAC8 441/4885 |
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | POLI, POLR2A, POLR2B | HDAC1 489/4885HDAC2 551/4885HDAC8 156/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | HDAC1 813/4885HDAC2 1235/4885HDAC8 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.